Johnson & Johnson Reports Strong Q1 2025 Earnings, But Faces Challenges in Profit Margins

Johnson & Johnson (NYSE: JNJ) Financial Update - Q1 2025

Key Financial Highlights:

• Total Revenue: $21.9 billion, up 2.4% YoY
• Net Earnings: $10.999 billion (50.2% of sales), compared to $3.255 billion last year
• Earnings Per Share (EPS): $4.57 (basic), $4.54 (diluted)
• Gross Profit Margin: 66.4%, down from 69.6% YoY
• Research and Development Expense: $3.225 billion (14.7% of sales), down from 16.6% YoY
• Total Assets: $193.671 billion, up from $180.104 billion
• Total Liabilities: $115.562 billion, up from $108.614 billion
• Cash and Cash Equivalents: $38.474 billion

Positive Aspects:

• Significant increase in net earnings driven by the reversal of a $7 billion talc reserve, leading to a profitable quarter.
• Strong sales growth in the Innovative Medicine segment ($13.9 billion), particularly driven by the Oncology and Immunology sectors despite some declines.
• Cash balance increased significantly, providing robust liquidity to fund operations and future acquisitions.

Negative Aspects:

• Cost of goods sold increased to 33.6% of sales due to unfavorable product mix and fair value inventory step-up associated with recent acquisitions.
• Decline in gross profit margin from 69.6% to 66.4%, indicating increasing costs impacting profitability.
• Ongoing litigation related to talc products continues to pose a risk for potential liabilities.

Overall, Johnson & Johnson's quarterly performance shows strong earnings growth primarily due to accounting factors rather than operational improvements, while also highlighting challenges in maintaining profit margins and ongoing legal pressures.